Motus GI (MOTS)

[Monksdream]

MOTS new 52 week low

[Monksdream]

MOTS new 52 week low

[Monksdream]

MOTS new 52 week low

[Monksdream]

MOTS new 52 week low

[Monksdream]

MOTS new 52 week low

[Monksdream]

MOTS new 52 Week low

[Triple nickle]

Adding down here

[ironhammer]

great news and vol

[INFINITI]

Slap that ask $$$$$

[janeyH]

Market cap.Micro Cap ($4.98M)

Maybe we write a check for the whole freakin thing?

[stock1ace1]

Awaiting news —> Motus said potential strategic alternatives, ranging from an acquisition, sale of assets and licensing, among others, is intended to position it to explore all alternatives, continue supporting existing customers using Pure-Vu EVS for colonoscopies, and target pipeline opportunities with contracted health systems.

[stock1ace1]

MOTS $1.10 ** 50ma break ** —> https://stockcharts.com/h-sc/ui?s=Mots

[Just-Keep-Trying]

MOTS: Coming back UP; don't give-up on this one today, Peeps. (Can I call ya all 'Peeps'? Or perhaps: HomeBoys, HomeGirls, RoadDogs, or straight-up MOTS Company GANG-BANGERS? HA-HA!!)

[Just-Keep-Trying]

MOTS: But NOT for the pre-surgical, inter alia, procedures required in the subject cases; this could run hard today (hopefully). THANKS for your Post here!

[Triple nickle]

Water fasting does this too

[Just-Keep-Trying]

MOTS (NASDAQ): This little puppy might land on the MOON Monday! My E-Turd page has it pumped-up by 67% right now --- 9:25 p.m., (balmy) San Diego, CA, Time --- in E-Turd's "Extended Hours" view! (Are you feelin' lucky???)

“We are pleased to report that topline data from the EU study show our Pure-Vu Gen2 system was able to improve the adequate cleansing rate from 31.8% to 97.7% in patients with a history of poor bowel preparation."
https://www.globenewswire.com/en/news-release/2022/05/24/2449753/0/en/Motus-GI-Announces-Positive-Topline-Data-From-EU-Study-of-the-Pure-Vu-System-in-Hard-to-Prepare-Patients-Presented-at-Digestive-Disease-Week-2022.html


"Ever see that NAVAGE thing, that's supposed to clean-out your big, stupid, NOSE? Well, this MOTS gadget can blow-out your big, fat, & greasy A-HOLE --- just before surgery! I want one for CHRISTMAS!"

[shimanoman]

Junk report, and with covid raging no one is getting elective colonoscopies or exams

[Investor004]

I just took a position with MOTS; my doctor wants me to have a colonoscopy; so I figured the company would be an investment to think about for the future of us all.

[ClayTrader]

* * $MOTS Video Chart 04-30-2021 * *

Link to Video - click here to watch the technical chart video

[trendzone]

Big FDA news out this morning

[ClayTrader]

* * $MOTS Video Chart 02-18-2021 * *

Link to Video - click here to watch the technical chart video

[Pennybuster]

$MOTS Starting a Position.

[janeyH]

moving again pre market

[janeyH]

Should we pat each other on the back

[janeyH]

agreed - this is due for a pop.

- increasing volume
- insider buying
- low float
- good products

no reason this shouldn't be at a 52-week high - 2.77

[soldier543]

this stock is going to go through the roof.According to the OTC board ,there has been 15 insiders buying in the last 6 months with NO insider selling.This tells me something.Hold on to your hats.




My opinion only .Do your own DD

[The Lawman]

Motus has doubled since IPO, and exploded as of late on very high volume. It seems as if someone knows something. Buyout? Results on ongoing study?

[AAAtrades]

Huge potential market, approvals in major economies already, so now all they have to do is convince doctors medical facilities this is a product they need/improves patient outcomes.

The HUGE market potential here is compelling combined with the fact that so many people have had this test it seems to create a strong demand awareness for this stock for a better solution ?

14 million such procedures done in the USA alone ?

and they have a patent in china already ?

seems like a 1 billion dollar market cap is appropriate just based on the potential alone...

https://www.nytimes.com/2013/06/02/health/colonoscopies-explain-why-us-leads-the-world-in-health-expenditures.html

Colonoscopies offer a compelling case study. They are the most expensive screening test that healthy Americans routinely undergo — and often cost more than childbirth or an appendectomy in most other developed countries. Their numbers have increased manyfold over the last 15 years, with data from the Centers for Disease Control and Prevention suggesting that more than 10 million people get them each year, adding up to more than $10 billion in annual costs.

Largely an office procedure when widespread screening was first recommended, colonoscopies have moved into surgery centers — which were created as a step down from costly hospital care but are now often a lucrative step up from doctors’ examining rooms — where they are billed like a quasi operation. They are often prescribed and performed more frequently than medical guidelines recommend.

The high price paid for colonoscopies mostly results not from top-notch patient care, according to interviews with health care experts and economists, but from business plans seeking to maximize revenue; haggling between hospitals and insurers that have no relation to the actual costs of performing the procedure; and lobbying, marke

[The Lawman]

Motus GI (MOTS) is a stock for anyone who has ever had, or is going to have, a colonoscopy.

The company's FDA approved product allows for a significant reduction in the prep needed for a colonoscopy. Anyone who has done this prep will realize just how valuable this product is.

MOTS just recently went public at $5, and after a quick drop, appears to be getting its sea legs.

Would like to get some comments from other investors, or prospective investors, in this stock.